Full Press Release Details
Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
SGMT
Therapeutic efficacy of FASN inhibition in preclinical models of HCC
Key Takeaway: Therapeutic efficacy of FASN inhibition in preclinical models of HCC
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+110%
120-day peak, hindsight
Typical move
5.7%
average across 12 past catalysts
Cash runway
~69 mo
Minimal dilution risk
Lead asset
TVB-2640
Phase 2 · Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease